Latest Breaking News On - David caouette - Page 5 : comparemela.com

Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzu

BOTHELL, Wash. (BUSINESS WIRE) Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its primary endpoint of progression-free survival (PFS). Patients in the trial had u.

United statesRoger danseyDavid caouetteExchange commissionCancer statistics centerSeagen incRoche groupBreast cancer development programLab abnormalitiesAmerican cancer societyChief medical officerResponse evaluation criteriaSolid tumorsCancer developmentFetal toxicityHepatic impairment

Six-Year Overall Survival Results Added to U S Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma

Six-Year Overall Survival Results Added to U S Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesDavid epsteinDavid caouetteAmerican society of clinical oncologyEuropean hematology associationSeagen incExchange commissionAmerican societyClinical oncologyEuropean hematologyChief executive officerImportant safety informationPrescribing informationQuarterly report

Seagen (SGEN) Reports Six-Year Overall Survival Results Added to U S Prescribing Information for ADCETRIS

Seagen (SGEN) Reports Six-Year Overall Survival Results Added to U S Prescribing Information for ADCETRIS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesDavid epsteinDavid caouetteSeagen incExchange commissionAmerican society of clinical oncologyEuropean hematology associationAmerican societyClinical oncologyEuropean hematologyChief executive officerImportant safety informationPrescribing informationQuarterly report

Seagen Inc : Seagen Announces ADCETRIS (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Seagen Inc : Seagen Announces ADCETRIS (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDistrict of columbiaDavid caouetteJeremy abramsonDouglas maffeiRoger danseyJo ann hagler centerEuropean hematology associationGerman hodgkin study groupInternational agency for research on cancerSeagen incInternational conference on malignant lymphomaExchange commissionInternational conferenceMalignant lymphomaSwitzerland june

Seagen Stockholders Approve Acquisition by Pfizer

Seagen Stockholders Approve Acquisition by Pfizer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDouglas maffeiDavid epsteinDavid caouetteExchange commissionCorporate communicationsEuropean unionSeagen incChief executive officerPrivate securities litigation reform actInvestor relations